It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The COVID-19 pandemic had a profound global impact, characterized by a high fatality rate and the emergence of enduring consequences known as Long COVID. Our study sought to determine the prevalence of Long COVID syndrome within a population of Northeastern Mexico, correlating it with patients' comorbidities, number of COVID-19 reinfection, and vaccination status. Employing an observational cross-sectional approach, we administered a comprehensive questionnaire covering medical history, demographics, vaccination status, COVID-related symptoms, and treatment. Our participant cohort included 807 patients, with an average age of 41.5 (SD 13.6) years, and women accounting 59.3% of the cohort. The follow-up was 488 (IQR 456) days. One hundred sixty-eight subjects (20.9%) met Long COVID criteria. Long COVID-19 was more prevalent when subjects had reinfections (p = 0.02) and less frequent when they had a complete vaccination scheme (p = 0.05). Through logistic regression, we found that male gender (OR 0.5, p ≤ 0.001), blood types of AB− (OR 0.48, p = 0.003) and O− (OR 0.27, p ≤ 0.001) in comparison with A+ and two doses of vaccines (OR 0.5, p = 006) to be protective factors against Long COVID; while higher BMI (OR 1.04, p = 0.005) was a risk factor. We saw that the prevalence of Long COVID was different within vaccinated patients and specific blood types, while being female and a higher BMI were associated with an increased risk of having long-COVID.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hospital Clínica Nova de Monterrey, Research Department, San Nicolás de los Garza, México; Universidad de Monterrey, Escuela de Medicina, Vicerrectoría de Ciencias de la Salud, San Pedro Garza García, México (GRID:grid.440451.0) (ISNI:0000 0004 1766 8816)
2 Universidad de Monterrey, Escuela de Medicina, Vicerrectoría de Ciencias de la Salud, San Pedro Garza García, México (GRID:grid.440451.0) (ISNI:0000 0004 1766 8816); Hospital Clínica Nova de Monterrey, Internal Medicine Department, San Nicolás de los Garza, México (GRID:grid.440451.0)
3 Hospital Clínica Nova de Monterrey, Research Department, San Nicolás de los Garza, México (GRID:grid.440451.0); Universidad de Monterrey, Escuela de Medicina, Vicerrectoría de Ciencias de la Salud, San Pedro Garza García, México (GRID:grid.440451.0) (ISNI:0000 0004 1766 8816)
4 Hospital Clínica Nova de Monterrey, Research Department, San Nicolás de los Garza, México (GRID:grid.440451.0)
5 Universidad de Monterrey, Escuela de Medicina, Vicerrectoría de Ciencias de la Salud, San Pedro Garza García, México (GRID:grid.440451.0) (ISNI:0000 0004 1766 8816)
6 IRCCS Humanitas Research Hospital, Rozzano, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807); Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy (GRID:grid.452490.e) (ISNI:0000 0004 4908 9368)